Eli Lilly's 'game-changing' diabetes drug could boost the stock, SVB Securities says - CNBC

Eli Lilly's new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company's stock, according to SVB Securities.

Eli Lilly 's new diabetes drug, which may also address obesity in patients, could lead to even more gains for the company's stock, according to SVB Securities. Analyst David Risinger initiated covera… [+2183 chars]

full article...